Palvella Therapeutics, Inc.
PVLA
$24.12
$0.2951.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 389.94% | 154.25% | 311.38% | 49.90% | -18.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 347.47% | 208.33% | 225.95% | -33.30% | -60.47% |
| Operating Income | -347.47% | -208.33% | -225.95% | 33.30% | 60.47% |
| Income Before Tax | -222.75% | -119.24% | -139.23% | -154.21% | -615.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -222.75% | -119.24% | -139.23% | -154.21% | -615.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -222.75% | -119.24% | -139.23% | -154.21% | -615.45% |
| EBIT | -347.47% | -208.33% | -225.95% | 33.30% | 60.47% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 51.81% | -127.71% | -130.32% | -343.79% | -1,542,100.00% |
| Normalized Basic EPS | 48.12% | -14.06% | -119.20% | -154.22% | -1,764.31% |
| EPS Diluted | 51.81% | -127.71% | -130.32% | -346.23% | -1,542,100.00% |
| Normalized Diluted EPS | 48.12% | -14.06% | -119.20% | -155.32% | -1,764.31% |
| Average Basic Shares Outstanding | 522.17% | 92.52% | 0.00% | 0.00% | -69.05% |
| Average Diluted Shares Outstanding | 522.17% | 92.52% | 0.00% | -2.00% | -69.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |